Display options
Cite
Wang Y, Hylemon PB, Zhou H. Long Noncoding RNA H19: A Key Player in Liver Diseases. Hepatology. 2021;74(3):1652-1659doi: 10.1002/hep.31765.
Wang, Y., Hylemon, P. B., & Zhou, H. (2021). Long Noncoding RNA H19: A Key Player in Liver Diseases. Hepatology (Baltimore, Md.), 74(3), 1652-1659. https://doi.org/10.1002/hep.31765
Wang, Yanyan, et al. "Long Noncoding RNA H19: A Key Player in Liver Diseases." Hepatology (Baltimore, Md.) vol. 74,3 (2021): 1652-1659. doi: https://doi.org/10.1002/hep.31765
Wang Y, Hylemon PB, Zhou H. Long Noncoding RNA H19: A Key Player in Liver Diseases. Hepatology. 2021 Sep;74(3):1652-1659. doi: 10.1002/hep.31765. Epub 2021 Aug 30. PMID: 33630308.
Copy Download .nbib Format: NLM
Share it on

Hepatology. 2021 Sep;74(3):1652-1659. doi: 10.1002/hep.31765. Epub 2021 Aug 30.

Long Noncoding RNA H19: A Key Player in Liver Diseases.

Hepatology (Baltimore, Md.)

Yanyan Wang, Phillip B Hylemon, Huiping Zhou

Affiliations

  1. Department of Microbiology and Immunology, Medical College of Virginia and McGuire Veterans Affairs Medical Center, Virginia Commonwealth University, Richmond, VA.

PMID: 33630308 DOI: 10.1002/hep.31765

[No abstract available.]

References

  1. Uszczynska-Ratajczak B, Lagarde J, Frankish A, Guigó R, Johnson R. Towards a complete map of the human long non-coding RNA transcriptome. Nat Rev Genet 2018;19:535-548. - PubMed
  2. Bao Z, Yang Z, Huang Z, Zhou Y, Cui Q, Dong D. LncRNADisease 2.0: an updated database of long non-coding RNA-associated diseases. Nucleic Acids Res 2019;47:D1034-D1037. - PubMed
  3. Brannan CI, Dees EC, Ingram RS, Tilghman SM. The product of the H19 gene may function as an RNA. Mol Cell Biol 1990;10:28-36. - PubMed
  4. Jarroux J, Morillon A, Pinskaya M. History, discovery, and classification of lncRNAs. Adv Exp Med Biol 2017;1008:1-46. - PubMed
  5. Wang C, Deng J, Deng H, Kang Z, Huang Z, Ding Z, et al. A novel Sox9/lncRNA H19 axis contributes to hepatocyte death and liver fibrosis. Toxicol Sci 2020;177:214-225. - PubMed
  6. Alipoor B, Parvar SN, Sabati Z, Ghaedi H, Ghasemi H. An updated review of the H19 lncRNA in human cancer: molecular mechanism and diagnostic and therapeutic importance. Mol Biol Rep 2020;47:6357-6374. - PubMed
  7. Udompap P, Kim D, Kim WR. Current and future burden of chronic nonmalignant liver disease. Clin Gastroenterol Hepatol 2015;13:2031-2041. - PubMed
  8. Gabory A, Jammes H, Dandolo L. The H19 locus: role of an imprinted non-coding RNA in growth and development. Bioessays 2010;32:473-480. - PubMed
  9. Rachmilewitz J, Goshen R, Ariel I, Schneider T, De Groot N, Hochberg A. Parental imprinting of the human H19 gene. FEBS Lett 1992;309:25-28. - PubMed
  10. Keniry A, Oxley D, Monnier P, Kyba M, Dandolo L, Smits G, et al. The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r. Nat Cell Biol 2012;14:659-665. - PubMed
  11. Ghafouri-Fard S, Esmaeili M, Taheri M. H19 lncRNA: roles in tumorigenesis. Biomed Pharmacother 2020;123:109774. - PubMed
  12. Barsyte-Lovejoy D, Lau SK, Boutros PC, Khosravi F, Jurisica I, Andrulis IL, et al. The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. Cancer Res 2006;66:5330-5337. - PubMed
  13. Basak P, Chatterjee S, Weger S, Bruce MC, Murphy LC, Raouf A. Estrogen regulates luminal progenitor cell differentiation through H19 gene expression. Endocr Relat Cancer 2015;22:505-517. - PubMed
  14. Wang WT, Ye H, Wei PP, Han BW, He B, Chen ZH, et al. LncRNAs H19 and HULC, activated by oxidative stress, promote cell migration and invasion in cholangiocarcinoma through a ceRNA manner. J Hematol Oncol 2016;9:117. - PubMed
  15. Moon Y, Kim I, Chang S, Park B, Lee S, Yoo S, et al. Hypoxia regulates allele-specific histone modification of the imprinted H19 gene. Biochim Biophys Acta Gene Regul Mech 2020;1863:194643. - PubMed
  16. Li X, Liu R, Yang J, Sun L, Zhang L, Jiang Z, et al. The role of long noncoding RNA H19 in gender disparity of cholestatic liver injury in multidrug resistance 2 gene knockout mice. Hepatology 2017;66:869-884. - PubMed
  17. Giovarelli M, Bucci G, Ramos A, Bordo D, Wilusz CJ, Chen C-Y, et al. H19 long noncoding RNA controls the mRNA decay promoting function of KSRP. Proc Natl Acad Sci U S A 2014;111:E5023-E5028. - PubMed
  18. Younossi ZM, Rinella ME, Sanyal A, Harrison SA, Brunt E, Goodman Z, et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology 2020 Jun 16. https://doi.org/10.1002/hep.31420. [Epub ahead of print] - PubMed
  19. Tilg H, Adolph TE, Moschen AR. Multiple parallel hits hypothesis in NAFLD-revisited after a decade. Hepatology 2020;73:833-842. - PubMed
  20. Zou T, Jaladanki SK, Liu L, Xiao L, Chung HK, Wang J-Y, et al. H19Long noncoding RNA regulates intestinal epithelial barrier function via microRNA 675 by interacting with RNA-binding protein HuR. Mol Cell Biol 2016;36:1332-1341. - PubMed
  21. Yu T-X, Chung HK, Xiao L, Piao J-J, Lan S, Jaladanki SK, et al. Long noncoding RNA H19 impairs the intestinal barrier by suppressing autophagy and lowering Paneth and goblet cell function. Cell Mol Gastroenterol Hepatol 2020;9:611-625. - PubMed
  22. Zhang Y, Liu C, Barbier O, Smalling R, Tsuchiya H, Lee S, et al. Bcl2 is a critical regulator of bile acid homeostasis by dictating Shp and lncRNA H19 function. Sci Rep 2016;6:20559. - PubMed
  23. Liu C, Yang Z, Wu J, Zhang LI, Lee S, Shin D-J, et al. Long noncoding RNA H19 interacts with polypyrimidine tract-binding protein 1 to reprogram hepatic lipid homeostasis. Hepatology 2018;67:1768-1783. - PubMed
  24. Liu J, Tang T, Wang GD, Liu B. LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARgamma axis in non-alcoholic fatty liver disease. Biosci Rep 2019;39:BSR20181722. - PubMed
  25. Wang H, Cao Y, Shu L, Zhu Y, Peng QI, Ran L, et al. Long non-coding RNA (lncRNA) H19 induces hepatic steatosis through activating MLXIPL and mTORC1 networks in hepatocytes. J Cell Mol Med 2020;24:1399-1412. - PubMed
  26. Onofrio FQ, Hirschfield GM. The pathophysiology of cholestasis and its relevance to clinical practice. Clin Liv Dis 2020;15:110-114. - PubMed
  27. Kwong E, Li Y, Hylemon PB, Zhou H. Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism. Acta Pharm Sin B 2015;5:151-157. - PubMed
  28. Takahashi K, Yan I, Haga H, Patel T. Long noncoding RNA in liver diseases. Hepatology 2014;60:744-753. - PubMed
  29. Li X, Liu R, Huang Z, Gurley EC, Wang X, Wang J, et al. Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and humans. Hepatology 2018;68:599-615. - PubMed
  30. Li X, Liu R, Wang Y, Zhu W, Zhao D, Wang X, et al. Cholangiocyte-derived exosomal lncRNA H19 promotes macrophage activation and hepatic inflammation under cholestatic conditions. Cells 2020;9:190. - PubMed
  31. Liu R, Li X, Zhu W, Wang Y, Zhao D, Wang X, et al. Cholangiocyte-derived exosomal long noncoding RNA H19 promotes hepatic stellate cell activation and cholestatic liver fibrosis. Hepatology 2019;70:1317-1335. - PubMed
  32. Song Y, Liu C, Liu X, Trottier J, Beaudoin M, Zhang LI, et al. H19 promotes cholestatic liver fibrosis by preventing ZEB1-mediated inhibition of epithelial cell adhesion molecule. Hepatology 2017;66:1183-1196. - PubMed
  33. Wang Z, Yang X, Kai J, Wang F, Wang Z, Shao J, et al. HIF-1alpha-upregulated lncRNA-H19 regulates lipid droplet metabolism through the AMPKalpha pathway in hepatic stellate cells. Life Sci 2020;255:117818. - PubMed
  34. Wang Z-M, Xia S-W, Zhang T, Wang Z-Y, Yang X, Kai J, et al. LncRNA-H19 induces hepatic stellate cell activation via upregulating alcohol dehydrogenase III-mediated retinoic acid signals. Int Immunopharmacol 2020;84:106470. - PubMed
  35. Xiao Y, Liu R, Li X, Gurley EC, Hylemon PB, Lu Y, et al. Long noncoding RNA H19 contributes to cholangiocyte proliferation and cholestatic liver fibrosis in biliary atresia. Hepatology 2019;70:1658-1673. - PubMed
  36. Zhang L, Yang Z, Huang W, Wu J. H19 potentiates let-7 family expression through reducing PTBP1 binding to their precursors in cholestasis. Cell Death Dis 2019;10:168. - PubMed
  37. Zhu J, Luo Z, Pan Y, Zheng W, Li W, Zhang Z, et al. H19/miR-148a/USP4 axis facilitates liver fibrosis by enhancing TGF-beta signaling in both hepatic stellate cells and hepatocytes. J Cell Physiol 2019;234:9698-9710. - PubMed
  38. Yang J-J, She Q, Yang Y, Tao H, Li J. DNMT1 controls lncRNA H19/ERK signal pathway in hepatic stellate cell activation and fibrosis. Toxicol Lett 2018;295:325-334. - PubMed
  39. Huang T-J, Ren J-J, Zhang Q-Q, Kong Y-Y, Zhang H-Y, Guo X-H, et al. IGFBPrP1 accelerates autophagy and activation of hepatic stellate cells via mutual regulation between H19 and PI3K/AKT/mTOR pathway. Biomed Pharmacother 2019;116:109034. - PubMed
  40. Tietze L, Kessler SM. The good, the bad, the question-H19 in hepatocellular carcinoma. Cancers 2020;12:1261. - PubMed
  41. Gamaev L, Mizrahi L, Friehmann T, Rosenberg N, Pappo O, Olam D, et al. The pro-oncogenic effect of the lncRNA H19 in the development of chronic inflammation-mediated hepatocellular carcinoma. Oncogene 2020;40:127-139. - PubMed
  42. Liu Y, Xu L, Lu B, Zhao M, Li L, Sun W, et al. LncRNA H19/microRNA-675/PPARalpha axis regulates liver cell injury and energy metabolism remodelling induced by hepatitis B X protein via Akt/mTOR signalling. Mol Immunol 2019;116:18-28. - PubMed
  43. Zhang J, Han C, Ungerleider N, Chen W, Song K, Wang Y, et al. A transforming growth factor-β and H19 signaling axis in tumor-initiating hepatocytes that regulates hepatic carcinogenesis. Hepatology 2019;69:1549-1563. - PubMed
  44. Sun Z, Xue S, Zhang M, Xu H, Hu X, Chen S, et al. Aberrant NSUN2-mediated m5C modification of H19 lncRNA is associated with poor differentiation of hepatocellular carcinoma. Oncogene 2020;39:6906-6919. - PubMed
  45. Xu Y, Liu Y, Li Z, Li H, Li X, Yan L, et al. Long non-coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR-675. Oncol Rep 2020;44:165-173. - PubMed
  46. Ye Y, Guo J, Xiao P, Ning J, Zhang R, Liu P, et al. Macrophages-induced long noncoding RNA H19 up-regulation triggers and activates the miR-193b/MAPK1 axis and promotes cell aggressiveness in hepatocellular carcinoma. Cancer Lett 2020;469:310-322. - PubMed

Publication Types

Grant support